2018
Scoring System to Optimize Pioglitazone Therapy After Stroke Based on Fracture Risk
Viscoli CM, Kent DM, Conwit R, Dearborn JL, Furie KL, Gorman M, Guarino PD, Inzucchi SE, Stuart A, Young LH, Kernan WN, Investigators F. Scoring System to Optimize Pioglitazone Therapy After Stroke Based on Fracture Risk. Stroke 2018, 50: 95-100. PMID: 30580725, PMCID: PMC6557695, DOI: 10.1161/strokeaha.118.022745.Peer-Reviewed Original ResearchTransient ischemic attackAbsolute risk differenceFracture riskIschemic attackPioglitazone therapyFracture risk modelsIschemic strokeMyocardial infarctionRisk strataRisk differenceRandomized placebo-controlled trialFavorable benefit-risk profilePlacebo-controlled trialLow-risk patientsEffect of pioglitazoneBody mass indexHigh-risk groupBenefit-risk profileHigh-risk stratumLow-risk groupSimple point scoreBone fracture riskCardiovascular riskPatient characteristicsDiabetes mellitus
2016
Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial
Viscoli CM, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, Gorman M, Kelly MA, Lovejoy AM, Kernan WN, Investigators F. Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial. The Journal Of Clinical Endocrinology & Metabolism 2016, 102: 914-922. PMID: 27935736, PMCID: PMC5460686, DOI: 10.1210/jc.2016-3237.Peer-Reviewed Original ResearchConceptsTransient ischemic attackIschemic strokeFracture riskBone fracturesRisk/benefit ratioAbsolute fracture riskInsulin Resistance InterventionPlacebo-treated patientsIschemic attackNondiabetic patientsPlacebo groupCardiovascular riskBone healthStroke trialsNondiabetic participantsPrevent fallsClinical trialsRelative riskSafety dataFracture classificationQuarterly interviewsPioglitazonePatientsResistance InterventionRisk increment
2010
Five-Year Outcomes in High-Risk Participants in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) Study A post hoc analysis
Bansal S, Wackers FJ, Inzucchi SE, Chyun DA, Davey JA, Staib LH, Young LH, . Five-Year Outcomes in High-Risk Participants in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) Study A post hoc analysis. Diabetes Care 2010, 34: 204-209. PMID: 20929989, PMCID: PMC3005488, DOI: 10.2337/dc10-1194.Peer-Reviewed Original ResearchConceptsCardiac event rateBaseline cardiovascular riskAnnual cardiac event rateHigh cardiovascular riskCardiovascular riskHigh-risk participantsDetection of ischemiaEvent ratesInducible ischemiaRisk engineUK Prospective Diabetes Study risk engineHigh baseline cardiovascular riskAsymptomatic Diabetics (DIAD) studyFive-year outcomesUKPDS risk engineLow-risk groupRisk stratification approachStudy of DiabetesLow-risk participantsAsymptomatic diabeticsCardiac eventsFramingham scoreMetabolic syndromeRisk groupsDiabetic study
2007
Insulin Sensitivity, Vascular Function, and Iron Stores in Voluntary Blood Donors
Zheng H, Patel M, Cable R, Young L, Katz SD. Insulin Sensitivity, Vascular Function, and Iron Stores in Voluntary Blood Donors. Diabetes Care 2007, 30: 2685-2689. PMID: 17630263, DOI: 10.2337/dc07-0748.Peer-Reviewed Original ResearchConceptsWhole-body insulin sensitivity indexFlow-mediated dilationOral glucose loadingVascular functionBlood donorsIron storesBlood donationBrachial arterySerum ferritinGlucose loadingInsulin sensitivityGlucose metabolismOral glucose tolerance testingProspective cross-sectional studyImproved vascular functionGlucose tolerance testingInsulin sensitivity indexVoluntary blood donorsCross-sectional studyHigh-frequency donorsCardiovascular riskAcute hyperglycemiaGlucose toleranceSerum markersTolerance testing
2005
Evaluating the Cardiovascular Effects of the Thiazolidinediones and Their Place in the Management of Type 2 Diabetes in Relation to the Metabolic Syndrome
Drexler AJ, Nesto RW, Abrahamson MJ, Bakris G, Bell D, Brunzell J, Dandona P, Davidson J, Fonseca V, Fowler M, Frye R, Giles T, Haffner S, Hollenberg N, Hsueh W, Law R, Plutzky J, Ratner R, Reusch J, Selwyn A, Sowers J, Wyne K, Young LH. Evaluating the Cardiovascular Effects of the Thiazolidinediones and Their Place in the Management of Type 2 Diabetes in Relation to the Metabolic Syndrome. Metabolic Syndrome And Related Disorders 2005, 3: 147-173. PMID: 18370723, DOI: 10.1089/met.2005.3.147.Peer-Reviewed Original ResearchType 2 diabetesMetabolic syndromeBeta-cell functionCardiovascular effectsEndothelial dysfunctionVascular reactivityInsulin sensitivityFuture cardiovascular eventsAdverse clinical eventsCoronary artery diseasePositive cardiovascular effectsCardiovascular disease burdenPotential adverse eventsProgression of diabetesInsulin-sensitizing effectsCardiovascular eventsCardiovascular outcomesAdverse eventsCardiovascular riskArtery diseaseGlycemic controlClinical eventsInsulin resistanceDisease burdenRisk factors